Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2372
    -0.0066 (-0.53%)
     
  • Bitcoin GBP

    51,852.49
    +634.55 (+1.24%)
     
  • CMC Crypto 200

    1,383.65
    +71.03 (+5.41%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.21
    +0.48 (+0.58%)
     
  • GOLD FUTURES

    2,403.00
    +5.00 (+0.21%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Company News For Nov 8, 2017

Is (PSEC) Outperforming Other Finance Stocks This Year?
  • Shares of Avis Budget Group, Inc. CAR fell 15.1% after reporting third-quarter revenues of $2,752 million, missing the Zacks Consensus Estimate of $2,776 million

  • Valeant Pharmaceuticals International, Inc’s VRX shares increased 17.1% after posting third-quarter adjusted earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.90

  • Shares of Mallinckrodt Public Limited Company MNK slumped 35.5% after reporting third-quarter revenues of $793.9 million, lower than the Zacks Consensus Estimate of $807 million

  • TrueCar, Inc’s TRUE shares plunged 35.3% after posting third-quarter revenues of $82.4 million, coming below the Zacks Consensus Estimate of $86.7 million


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Avis Budget Group, Inc. (CAR) : Free Stock Analysis Report
 
TrueCar, Inc. (TRUE) : Free Stock Analysis Report
 
Valeant Pharmaceuticals International, Inc. (VRX) : Free Stock Analysis Report
 
Mallinckrodt PLC (MNK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research